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Purpose: Using urinary indices as a quick bedside test to assist management of oliguria and acute 
kidney injury (AKI) has long been sought. This study assessed whether urinary potassium excretion 
is related to simultaneously calculated creatinine clearance (CrCl) and can predict AKI in the 
critically ill. 
Materials and methods: In this prospective cohort study, the correlation between 2-hour urinary 
potassium excretion and simultaneously calculated CrCl of 61 critically ill patients was assessed by 
Pearson’s correlation coefficient, and their ability to predict AKI (≥ stage 1 KDIGO) in the 
subsequent 7 days was assessed by area under the receiver-operating-characteristic (AUROC) 
curve. 
Results: Urinary potassium excretion (median 6.2mmol, range 0.8-24.3) correlated linearly with 
CrCl (correlation coefficient: 0.58, 95% confidence interval [CI] 0.38-0.72; p=0.001), and had a 
moderate ability to predict subsequent AKI (n=19 [31%]; AUROC 0.747, 95%CI 0.620-0.850; 
p=0.001), especially in patients without prior exposure to furosemide within 24-hours (correlation 
coefficient 0.61, 95%CI 0.41-0.76; AUROC 0.789, 95%CI 0.654-0.890; p=0.001, respectively). 
Conclusions: Urinary potassium excretion correlates with CrCl and predicts AKI in the critically ill 
without recent furosemide exposure. Given 2-hour urinary potassium excretion can be measured 





















AKI (Acute Kidney Injury) affects 22-67% of the critically ill [1,2] and is associated with significant 
morbidity and mortality [3]. In patients admitted to intensive care units (ICU) between 4 to 13.5% 
require renal replacement therapy (RRT)[4,5] and, within this highest risk group of patients, there is 
a 50-60% mortality with a further 5-20% remain dependent on dialysis on hospital discharge [4]. 
Early identification of patients at high-risk of AKI facilitates risk stratification, avoidance of 
nephrotoxins, and proactive investigation of any possible untreated pathologies. Although many renal 
biomarkers (e.g. NGAL) have been shown to be sensitive in identifying patients before they develop 
AKI based on clinical criteria, their use as a bedside risk-stratifying tool remains limited, due to their 
availability, high cost, and also a slow turn-around time. 
 
Human body is a net potassium producer. In addition to adjusting the reabsorption from the 
glomerular filtrate, the kidney also has an ability to actively secrete potassium – primarily by H-K-
ATPase in the intercalated cells and Na-K-ATPase in principal cells (controlled by aldosterone) 
located in the distal convoluted tubule and collecting duct – to maintain potassium homeostasis. Due 
to a combination of reduction in glomerular filtration rate (GFR) and tubular function, a high plasma 
potassium concentration is not rare in patients with severe chronic renal failure. Evidence suggests 
that in chronic renal failure, those who maintain a reasonable amount of daily urinary potassium 
excretion have a better long-term prognosis than patients with a lower urinary potassium excretion 
[6]. In the general population without chronic renal failure, a high urinary potassium excretion has 
also been reported to be associated with a lower risk of cardiovascular events, hypertension [7], and 
death [8] compared to those who have a lower renal capacity to excrete potassium. 
 
A high fractional urinary excretion of potassium [FEK = (UK x PCr) x 100/(PK x UCr)], measured prior 
to the occurrence AKI, has been reported to be associated with an increased risk of persistent AKI for 

















creatinine clearance (CrCl), making it difficult to exclude a high FEK being a confounder in the 
relationship between reduced CrCl and poor renal outcomes. Currently, it is uncertain whether urinary 
potassium excretion is increased or decreased in AKI. As the kidney function fails, the renin-
angiotensin-aldosterone pathway is activated as a part of the AKI [10], which would enhance distal 
tubular potassium excretion [9]. On the other hand, a reduction in GFR and tubular potassium 
secretory function may dominate in determining how much potassium can be excreted in the urine, 
resulting in hyperkalemia commonly seen in severe AKI [9]. 
 
Numerous studies have looked at blood and urinary indices to try to establish their roles in identifying 
early AKI [11,12] prior to the rise in plasma urea and creatinine concentration. Historically, fractional 
sodium excretion (FENa), as a discriminator between prerenal and non-prerenal AKI, has been the 
main focus of investigation [13]. More recently FENa has also, unfortunately, been shown to be a poor 
discriminator between persistent and transient AKI in the critically ill care [14]. It is uncertain whether 
urinary potassium excretion would be more useful than urinary sodium excretion in identifying 
patients at risk of AKI in the acute care setting. We hypothesized that urinary potassium excretion is 
reduced in AKI, and may have a direct relationship to the calculated CrCl. In this pilot prospective 
cohort study, we aimed to assess whether urinary potassium excretion was linearly related to the 
calculated CrCl, and whether it could discriminate between patients who subsequently developed 






















After obtaining approval from the Clinical Safety and Quality Unit approval (No 14537), we aimed 
to recruit 50 critically ill patients (>16 years-old) admitted to Royal Perth Hospital Intensive Care 
Unit (ICU), between April and June 2017, into this pilot prospective cohort study. Patients who were 
admitted to the ICU within 24-hours with an indwelling urinary catheter and due to have early 
morning (6am) plasma electrolytes and renal function test were eligible for enrolment. Patients who 
were anuric (<100ml/day), already undergoing dialysis or RRT, with known pre-existing renal failure, 
or had previously been included in this study in their prior ICU admission were excluded. A total of 
61 patients was recruited by the end of the three-month study period.  
 
Urinary volume between 4am and 6am was recorded, and samples for urinary biochemical analyses 
were collected at 6am (from the urine collected between 4-6am) by the nursing staff in the first 
morning of a patient's admission to ICU (within the first 24-hours of ICU admission), immediately 
prior to the morning blood collection for plasma electrolytes and renal function test. The urinary 
sodium, potassium and creatinine concentrations were measured by the hospital biochemistry 
laboratory, using the Abbott Diagnostics® (ARCHITECT c16000) chemistry analyzer. All reagents 
and consumables used for the assays were provided by Abbott Diagnostics®. 
 
In addition to demographic data, Sequential Organ Failure Assessment (SOFA) score (on the day of 
enrolment), Acute Physiology and Chronic Health Evaluation (APACHE) II score, whether the 
patient had received furosemide or other diuretics within the 24-hours (including the type and dose) 
prior to enrolment, invasive/non-invasive respiratory support and vasopressors were also recorded. 
All patients were followed up to hospital discharge including data on the peak plasma creatinine 
concentration within 7 days of enrolment and during the whole hospital stay, KDIGO AKI grading 


















The total amount of urinary potassium excreted in 2-hours was calculated by multiplying the 2-hour 
urine sample potassium concentration (mmol/l) by the urine volume (litres in the 2 hours collection 
period) to give mmol of potassium excreted in 2 hours. We chose a 2-hour urine collection period for 
this study because of previous studies, including one on ICU patients, have shown that it correlates 
well with the calculated CrCl over a 24-hour period [15, 16].  
 







Categorical and continuous variables with skewed distributions were analysed by Chi Square and 
Mann Whitney tests, respectively. Pearson’s correlation coefficient was used to assess the degree of 
linear relationship between urinary potassium excretion and the calculated 2-hour CrCl, stratified by 
whether diuretic was given within 24 hours prior to study enrolment. Area under the receiver-
operating-characteristic (AUROC) curve was used to assess the ability of urinary potassium and 
sodium excretion (in 2 hours), SOFA score and calculated 2-hour CrCl to predict the risk of KDIGO 
AKI (stage 1 or higher) within 7 days of study enrolment. All statistical analyses were performed by 
SPSS for Windows (version 24.0, IBM, USA) and MedCalc® Statistical Software (version 17.9.6, 























The patient group was representative, for the most part, of our ICU population (Table 1). There was 
a slightly larger proportion of male patients (62%), primarily because the study center is Western 
Australia’s State Trauma Center and trauma patients constituted 25% of our study patients. The 
median APACHE II score was 15, 25% required mechanical ventilation and 36% were treated with 
vasopressors at the time of enrolment. The acuity of the study cohort was skewed towards the lower 
end, in part, due to excluding patients who had already started dialysis. Exclusion of these dialysed 
patients, in addition to the exclusion of those with pre-existing chronic renal impairment, may also 
explain why only a small proportion of our study patients eventually required RRT (5%).  In the 
patient group, 9 received frusemide in the 24 hours prior. No other diuretics were administered. 
 
Correlation between 2-hours urinary potassium excretion, urinary sodium excretion, SOFA 
scores and calculated CrCl 
 
The absolute quantity of urinary potassium excreted correlated with the calculated CrCl in a relatively 
linear fashion (Pearson’s correlation coefficient: 0.58, 95% confidence interval [CI] 0.38-0.72; 
p=0.001), especially when only patients without an exposure to diuretics within 24-hours prior to 
enrolment were considered (Pearson’s correlation coefficient 0.61, 95%CI 0.41-0.76) (Fig 1). Prior 
recent exposure to furosemide occurred in nine patients (15%) and, as expected from the actions of 
furosemide, the urinary potassium excretion was not significantly correlated with the calculated CrCl 
in these patients. Both plasma potassium concentrations (Pearson’s correlation coefficient -0.24, 
95%CI -0.47 to 0.01) and urine output alone (Pearson’s correlation coefficient 0.16, 95%CI -0.10 to 
0.39; p=0.233) had no significant correlation with the calculated CrCl (Fig 2 and Fig 3, respectively).  
 
Analyzing all patients as a whole, urinary sodium excretion had little correlation with the calculated 

















those who had recently received furosemide, a higher urinary sodium excretion – likely representing 
a good urinary response to furosemide – was significantly correlated with the calculated CrCl 
(Pearson’s correlation coefficient 0.79, 95%CI 0.27-0.96) [17].  
 
Although urinary potassium excretion obtained within the first 24-hours of ICU admission was not 
as good as the simultaneously calculated CrCl in predicting AKI within the subsequent 7 days after 
the urinary analyses, it still had a moderate ability to discriminate between patients with and without 
subsequent AKI (n=19 [31%]; AUROC 0.747, 95%CI 0.620-0.850; p=0.001) (Fig 5). This ability 
was further improved after restricting the analyses to patients who did not receive any furosemide 
within 24-hours prior to enrolment (AUROC 0.789, 95%CI 0.654-0.890; p=0.001) (Table 2), and 
was better than both SOFA score (AUROC 0.744, 95%CI 0.605-0.839; p=0.001) and urinary sodium 





















This pilot prospective cohort study showed that urinary potassium excretion had a reasonably linear 
correlation with the simultaneously calculated CrCl in the critically ill if they did not have recent 
exposure to diuretics. In addition, urinary potassium excretion also had a modest ability, and was 
better than both SOFA score and urinary sodium excretion, to predict patients who subsequently 
developed AKI. These findings have some clinical relevance and require further consideration. 
 
First, our results showed that the absolute amount of urinary potassium excretion has a reasonably 
strong positive correlation with the simultaneously calculated CrCl, but only in patients without 
recent exposure to diuretics. This finding is not surprising because plasma potassium is freely filtered 
through the glomeruli; the absolute amount of potassium excreted in the urine will be, at least in part, 
dependent on the GFR. Based on the mechanism of actions of furosemide, both the reabsorption of 
potassium in the ascending loop of Henle and secretion of potassium in the distal tubule and collecting 
duct would be affected by an exposure to furosemide, increasing urinary potassium excretion 
independent of the GFR. As such, any interpretation of urinary potassium excretion, either as a 
surrogate marker of CrCl or prognostic marker for subsequent AKI, is only valid for patients without 
recent (<24 hours) diuretics exposure. 
 
Second, given urinary potassium concentration can be easily measured by any biochemical 
laboratories and also many modern point-of-care blood gas analyzers, it may represent a simple test 
to alert clinicians about the renal status of their patients, better than using the SOFA score and urine 
output alone (Fig 5). Based on the AUROC curve of urinary potassium excretion, using a cut-point 
of urinary potassium excretion ≤3.8mmol in 2 hours would have a specificity of 85% and sensitivity 
of 77% (Youden index J=0.62) in predicting subsequent AKI (KDIGO stage ≥1) within 7 days of 

















CrCl or risk of subsequent AKI. In the first instance, for those without recent furosemide exposure, 
urinary sodium excretion had hardly any correlation with the simultaneously calculated CrCl. Even 
though our results showed that there was a reasonably high correlation between urinary sodium 
excretion and the calculated CrCl for those with recent exposure to furosemide, the range of the 
quantity of urinary sodium excreted between patients was narrow (<15mmol over 2 hours) – which 
can be potentially confounded by variations in dose, route of administration, and timing of urinary 
analyses – making it clinically not useful. 
 
Third, we need to acknowledge the limitations of our study. This was a pilot study aiming at testing 
the hypothesis of that there was a correlation between the calculated CrCl and urinary potassium 
excretion. In retrospect, the interpretation of our findings would be more comprehensive if we had 
included an equal number of patients with and without recent furosemide exposure. The population 
that was studied may also be atypical for other ICUs, as the state trauma center we have a 
proportionately larger number of trauma patients, this results in male being overrepresented and a 
younger population demographic. Trauma patients without prior renal impairment (as per exclusion 
criterion in this study) have a lower risk of developing AKI and, when it occurs, the 
pathophysiological mechanisms leading to AKI are likely different from sepsis – limiting the 
generalizability of our results to septic patients.  It should be noted that the correlation between 
urinary potassium excretion and the calculated CrCl or risk of subsequent AKI would theoretically 
be weakened by any variations in dietary intake of potassium and extra-renal loss of potassium. These 
two extra-renal factors would only have affected urinary potassium excretion, but not the calculated 
CrCl or risk of AKI, resulting in a weaker ability for urinary potassium to correlate or predict these 
two outcomes. 
 
We also noted that some of our study patients had augmented CrCl related to over-representation of 

















between CrCl and potassium excretion [19]. Additionally, as we enrolled patients at their first routine 
blood collection (4-6am approx.) we lost the opportunity to study patients who required RRT between 
ICU admission and the time of morning blood test the day after. Coupled with the exclusion criteria, 
this could, in part, explain the lower acuity of our study patients and the low rate of progressing to 
requiring RRT. We could not confirm whether urinary potassium excretion would be useful in 
predicting risk of subsequent RRT in the critically ill, due to low numbers. A large multicentre 
prospective study will be important to assess whether urinary potassium excretion can be used to 
predict risk of severe AKI requiring RRT in the critically ill.  
 
 
In summary, this pilot prospective study indicates that urinary potassium excretion correlates 
relatively linearly with CrCl, and can predict AKI in the critically ill in patients without recent 
furosemide exposure. Given 2-hour urinary potassium excretion can be measured easily, its potential 
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Table 1. Characteristics of the cohort (N=61). 
 
Variables Median (range) unless stated otherwise 
Age, yrs 51 (18-90) 
Male, no. (%) 38 (62) 
Diagnosis, no. (%)  
- Sepsis 8 (13) 
- Cardiac arrest 4 (6.5) 
- Trauma 15 (24.5) 
- Respiratory failure 4 (6.5) 
- Overdose / poisoning 3 (5) 
- Postoperative 14 (23) 
- Other 13 (21) 
Requiring vasopressor, no. (%) 15 (24.6) 
Requiring mechanical ventilation, no. (%) 22 (36.1) 
SOFA score on the study day 5 (0-17) 
Plasma creatinine, umol/l* 71 (36-451) 
2-hr urinary output, ml 110 (20-650) 
Measured 2-hr creatinine clearance, ml/min 114 (4.0-305) 
Plasma sodium, mmol/l 139 (131-153) 
Plasma potassium, mmol/l 4.0 (2.3-5.5) 
2-hr urinary sodium concentration, mmol/l 48 (7.5-214) 
2-hr urinary potassium concentration, mmol/l 59 (4-152) 
2-hr urinary sodium excretion, mmol 4.6 (0.03-64.3) 
2-hr urinary potassium excretion, mmol 6.2 (0.8-24.3) 
KDIGO AKI (stage ≥1) within 7 days, no. (%) 19 (31) 
Subsequent dialysis or CRRT, no. (%) 3 (5) 
Hospital mortality, no. (%) 8 (13) 
Furosemide within 24 hrs prior, no. (%) 9 (15) 
Length of hospital stay, days 12 (2–120) 
Length of ICU stay, days 3 (1-18) 
APACHE II score 15 (3–37) 
 
APACHE, Acute Physiology and Chronic Health Evaluation. CRRT, Continuous renal replacement 
therapy. KDIGO, Kidney Disease: Improving Global Outcomes. AKI, Acute Kidney Injury. SOFA, 



















Table 2. Ability of each predictor to discriminate between patients with and without developing 
acute kidney injury (KDIGO AKI stages 1-3) within 7 days of testing. 
 
AUROC (95%CI)  
Predictor Whole cohort* 
(N=61) 
































*19 patients (31%) developed stages 1-3 KDIGO AKI. #A cut-point of urinary potassium excretion 
≤3.8mmol in 2 hrs had a specificity of 85% and sensitivity of 77% (Youden index J=0.62) in 
predicting AKI (KDIGO stage ≥1) within 7 days of testing. 
AUROC, area under the receiver-operating-characteristic curve. CI, confidence interval. CrCl, 
creatinine clearance. KDIGO, Kidney Disease: Improving Global Outcomes. SOFA, Sequential 






















 Absolute urinary potassium is positively associated with creatinine clearance. 
 Urinary potassium excretion has a modest ability to predict renal failure. 
 Urinary potassium outperforms SOFA and urinary sodium at predicting renal failure. 
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